A significant decrease in serum TWEAK has been reported in RA patients responding to treatment with etanercept [13,14] while persistent TWEAK/Fn14 expression was seen in a RA patient cohort receiving infliximab treatment [14] suggesting a role for TWEAK in modulation of disease activity. Here, TNFRSF12A is linked to rheumatoid arthritis.